

Special Issue

Novel Biomarkers in Translational Medicine of Chronic and Autoimmune Diseases

Message from the Guest Editors

Inflammation is a normal physiological defence against pathogen infection and tissue damage and quickly ends under normal circumstances. However, in many chronic conditions, the inflammatory response continues and leads to significant tissue/organ damage. Chronic diseases are multifactorial diseases and considered a serious public health problem. The immune system plays a central role in many processes involving chronic diseases and subsequently cancer. New therapies have been proposed with potential positive impacts for patients, minimising morbidity and mortality. The aim of this Special Issue is to invite original research articles, notable clinical findings, and review articles that present and discuss the advancement of research and innovative therapies involving chronic diseases, the regulation of inflammation in the pathology and treatment of autoimmune diseases, the relationship between inflammation and cancer, the latest research about the immune system and chronic diseases, and advances in genetics and molecular diagnostics.

Guest Editors

Dr. Umberto Basile

Head of Clinical Pathology Unit, Hospital "Santa Maria Goretti" ASL Latina, Latina, Italy

Prof. Dr. Ettore Domenico Capoluongo

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, UNIVERSITA' DEGLI STUDI FEDERICO II, Facoltà di Medicina e Chirurgia "Federico II", Napoli, Italy

Deadline for manuscript submissions

closed (10 January 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed




mdpi.com/si/78704

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).